Amyris, Inc.
Case Number:
1:23-bk-11131
Court:
Nature of Suit:
Firms
- Rosner Law Group LLC
- Lewis Brisbois
- KTBS Law
- Holland & Knight
- Potter Anderson
- Margolis Edelstein
- Buchalter APC
- Archer & Greiner
- Ballard Spahr
- Pachulski Stang
- Benesch
- Golenbock Eiseman
- Womble Bond
- deLeeuw Law
- Landis Rath
- Kudman Trachten
- McCarter & English
- Connolly Gallagher
- AXS Law Group
- Cyrulnik Fattaruso
- Paul Weiss
- Linebarger Goggan
- Dunlap Bennett
- Bielli & Klauder
- Richards Layton
- Powell Firm
- Cole Schotz
- Fox Rothschild
- Blank Rome
- Nixon Peabody
- Morris Nichols
- Troutman Pepper
- White and Williams
- Duane Morris
- Monzack Mersky
- Tucker Arensberg
- Arnold & Porter
- Tannenbaum Helpern
- ArentFox Schiff
- Foley Hoag
- DLA Piper
- Barack Ferrazzano
- Goodwin Procter
- Ostrager Chong
- Morris James
- Streusand Landon
- Bragar Eagel
- Greenberg Traurig
- Paul Hastings
- Harris Beach PLLC
- MoloLamken
- Keller & Heckman
- Klehr Harrison
- Young Conaway
- Cross & Simon
- Latham & Watkins
- White & Case
Companies
- Sartorius AG
- Intrepid Investment Bankers
- U.S. Bancorp
- NTT Data Corp.
- Amyris Inc.
- Ankura Consulting Group LLC
- Microsoft Corp.
- Stretto Inc.
- Dr. Reddy's Laboratories Ltd.
- Hearst Corp.
- Thermo Fisher Scientific Inc.
- Cosan Limited
- Oracle Corp.
- Sephora SA
- Salesforce.com Inc.
- Google LLC
- Givaudan
- Jefferies Financial Group Inc.
Government Agencies
- Texas Comptroller of Public Accounts
- U.S. Securities and Exchange Commission
- State of Michigan
- Massachusetts Department of Revenue
Sectors & Industries:
-
March 18, 2024
Amyris Gets OK To Settle Pot Co.'s $15M Trade Secret Suit
A Delaware bankruptcy judge has approved biotechnology company Amyris' $15.1 million settlement with cannabinoid manufacturer Lavvan, resolving yearslong litigation and arbitration proceedings alleging the debtor misused its then-business partner's trade secrets.
-
February 02, 2024
Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan
A Delaware bankruptcy judge on Friday struck down biotechnology company Amyris Inc.'s plan to shield executives and others from liability using nonconsensual releases as part of its Chapter 11 plan, finding that Amyris can reorganize without relying on the controversial mechanism.
-
January 24, 2024
Amyris Says Claim Releases Needed For Post-Ch. 11 Success
Biotechnology company Amyris Inc. told a Delaware bankruptcy judge on Wednesday it needs to eliminate potential shareholder claims in order to emerge from its Chapter 11 case as a successful company.
-
January 18, 2024
SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan
The U.S. Securities and Exchange Commission and the U.S. Trustee's Office have expressed new concerns about nonconsensual third-party releases in biotechnology company Amyris' Chapter 11 plan, arguing that such releases are only allowed in extraordinary circumstances that were not met by the debtor.
-
January 09, 2024
Amyris Fights Claims In Cannabis IP Row By Defining 'Under'
Biotechnology company Amyris Inc. said Tuesday the word "under" in a contract between it and cannabinoid manufacturer Lavvan supports its effort to quash two claims Lavvan has filed against the debtor, telling a Delaware bankruptcy judge the plain meaning of the preposition bars the claims from going forward.
-
December 20, 2023
Biochemical Co. Amyris OK'd To Sell Celebrity Brands
Bankrupt biochemical company Amyris Inc. can move forward with plans to sell its remaining consumer brands, a Delaware bankruptcy judge ruled Wednesday, after an auction last week raked in winning bids totaling $6 million.
-
December 15, 2023
Amyris Says DIP Lender Will Bid For Remaining Assets
Synthesized biologicals producer Amyris told a Delaware bankruptcy court its debtor-in-possession and prepetition lenders will step in with a stalking horse credit bid for its core assets, unless the Northern California-based company receives a bid greater than $255 million at a Chapter 11 auction in January.
-
December 12, 2023
Amyris Gets OK To Solicit Ch. 11 Plan Votes
A Delaware bankruptcy judge Tuesday allowed biochemical company Amyris Inc. to send its Chapter 11 plan out for a creditor vote, overriding objections tied to the plan's proposed third-party claim releases.
-
December 11, 2023
Amyris Creditors Slam 'Tainted' Ch. 11 Plan
Noteholders and shareholders of bankrupt biochemical company Amyris Inc. have lodged an objection to its Chapter 11 plan and disclosure statement, contending the plan keeps creditors in the dark about the impact of its third-party releases and exemplifies a larger lack of transparency.
-
December 07, 2023
Amyris Files Ch. 11 Plan With $23M Creditor Deal
Biochemical company Amyris Inc. has filed a Chapter 11 plan disclosure statement saying it has reached a deal that could provide more than $23 million to unsecured creditors but that the proceeds of last week's auction of its brand assets were less than expected.